Sony Interactive Entertainment to Acquire Firesprite
8.9.2021 17:00:00 EEST | Business Wire | Press release
Sony Interactive Entertainment (“SIE”) announced today that SIE has entered into a definitive agreement to acquire Firesprite Limited, the UK-based videogame studio with a history of developing highly-polished showpieces for cutting-edge hardware. With a partnership spanning more than 8 years and a games portfolio highlighting PlayStation’s technological innovations, Firesprite will play a critical role in strengthening SIE’s exclusive games catalog in genres outside of PlayStation Studios’ core offerings.
Founded by industry veterans from SIE’s Studio Liverpool, Firesprite has a strong record of developing showcase games for PlayStation console and peripheral launches. Over the past few years, Firesprite has partnered with SIE to develop games for the PlayStation®4 and PlayStation®VR launch including The Playroom (PS4) and The Playroom VR (PS VR), both of which showcased unique hardware capabilities with highly-quality gameplay.
Originally a PS VR exclusive, with its most recent release, The Persistence, Firesprite pushed the boundaries of how users interact with the PS VR headset by introducing a groundbreaking virtual reality social element that further demonstrated the studio’s technical and creative capabilities. Later adapted for flat screens in 2018, Firesprite recently released The Persistence Enhanced in June 2021 which optimized the game for PlayStation®5 to include DualSense™ wireless controller haptic feedback, adaptive triggers, and raytraced rendering.
“We are delighted to welcome Firesprite into the PlayStation family,” said Jim Ryan, President & CEO, Sony Interactive Entertainment. “We have a rich history of working with the founders of Firesprite and are excited to grow the PlayStation presence in Liverpool. The portfolio of titles Firesprite has developed has continually demonstrated the team’s ability to transcend traditional gameplay experiences and brilliantly showcase the potential of our hardware.”
“Creating quality, state-of-the-art games has always been at the forefront of Firesprite’s work and I’m confident they will push the bar even further as part of PlayStation Studios,” said Hermen Hulst, Head of PlayStation Studios. “Firesprite’s ability to weave best-in-class gameplay with new technology is exceptional and I think fans will be excited about their creative vision for the future.”
“At Firesprite, we’re always striving to bring something new to a game or genre and developing for new technologies is a driving force of our passion,” said Graeme Ankers, Managing Director, Firesprite. “Joining PlayStation Studios will allow us to amplify this passion, working more closely on cutting-edge hardware without any limitations and furthering our studio’s heritage of creativity and technical innovation to offer some truly unique experiences for PlayStation fans.”
Based in Liverpool, UK Firesprite will join the global development operation of PlayStation Studios and will be the 14th studio to join the PlayStation Studios family. The day-to-day operations post-acquisition will continue to be run by Firesprite’s current management team. Terms of this transaction including the acquisition cost are not disclosed due to contractual commitments.
About Sony Interactive Entertainment
Recognized as a global leader in interactive and digital entertainment, Sony Interactive Entertainment (SIE) is responsible for the PlayStation® brand and family of products and services. PlayStation has delivered innovation to the market since the launch of the original PlayStation in Japan in 1994. The PlayStation family of products and services include PlayStation®5, PlayStation®4, PlayStation®VR, PlayStation™Store, PlayStation®Plus, PlayStation™Now, and acclaimed PlayStation software titles from PlayStation Studios. Headquartered in San Mateo, California, SIE is a wholly owned subsidiary of Sony Group Corporation and has global functions in California, London and Tokyo.
About Firesprite
Founded in 2012 by a group of creative and management veterans with years of industry experience, Firesprite is a visionary game development studio based in the heart of Liverpool’s vibrant game development hub with over 200 team members. Creating a number of showcase games for PlayStation console and peripheral launches over the years, Firesprite’s core focus is developing innovative and memorable experiences for players on cutting edge gaming hardware. At Firesprite, the end player experience always comes first and the team is passionate about how to best combine the disciplines of design, art and code to deliver experiences that surprise and delight.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005275/en/
Contact information
Brian Keltner
brian.keltner@sony.com
Joelle Messianu
joelle.messianu@sony.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom